GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Net Income Including Noncontrolling Interests

Veru (STU:FMW) Net Income Including Noncontrolling Interests : €-34.69 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Veru Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Veru's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2024 was €-7.69 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 was €-34.69 Mil.

Veru Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Veru's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Net Income Including Noncontrolling Interests Chart

Veru Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.11 6.29 -84.88 -87.28 -34.06

Veru Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.62 -7.59 -9.22 -10.19 -7.69

Veru Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Veru's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
COYA APLT ADVM EDIT NVCT RGLS HLVX ASMB MNOV ORMP VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
VERU:USA FMW:Germany
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Website
https://www.verupharma.com
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru Headlines

No Headlines